129 related articles for article (PubMed ID: 38906867)
1. A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection.
Zhong L; Zhang W; Liu H; Zhang X; Yang Z; Wen Z; Chen L; Chen H; Luo Y; Chen Y; Feng Q; Zeng MS; Zhao Q; Liu L; Krummenacher C; Zeng YX; Chen Y; Xu M; Zhang X
Nat Commun; 2024 Jun; 15(1):5310. PubMed ID: 38906867
[TBL] [Abstract][Full Text] [Related]
2. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
3. Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection.
Hong J; Zhong L; Liu L; Wu Q; Zhang W; Chen K; Wei D; Sun H; Zhou X; Zhang X; Kang YF; Huang Y; Chen J; Wang G; Zhou Y; Chen Y; Feng QS; Yu H; Li S; Zeng MS; Zeng YX; Xu M; Zheng Q; Chen Y; Zhang X; Xia N
Cell Rep Med; 2023 Nov; 4(11):101296. PubMed ID: 37992686
[TBL] [Abstract][Full Text] [Related]
4. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
[TBL] [Abstract][Full Text] [Related]
5. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
6. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies.
Sathiyamoorthy K; Jiang J; Möhl BS; Chen J; Zhou ZH; Longnecker R; Jardetzky TS
Proc Natl Acad Sci U S A; 2017 Oct; 114(41):E8703-E8710. PubMed ID: 28939750
[TBL] [Abstract][Full Text] [Related]
8. Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region.
Hong J; Wei D; Wu Q; Zhong L; Chen K; Huang Y; Zhang W; Chen J; Xia N; Zhang X; Chen Y
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960650
[TBL] [Abstract][Full Text] [Related]
9. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
10. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
11. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV.
Sun C; Kang YF; Fang XY; Liu YN; Bu GL; Wang AJ; Li Y; Zhu QY; Zhang H; Xie C; Kong XW; Peng YJ; Lin WJ; Zhou L; Chen XC; Lu ZZ; Xu HQ; Hong DC; Zhang X; Zhong L; Feng GK; Zeng YX; Xu M; Zhong Q; Liu Z; Zeng MS
Cell Host Microbe; 2023 Nov; 31(11):1882-1897.e10. PubMed ID: 37848029
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus.
Edwards KR; Schmidt K; Homad LJ; Kher GM; Xu G; Rodrigues KA; Ben-Akiva E; Abbott J; Prlic M; Newell EW; De Rosa SC; Irvine DJ; Pancera M; McGuire AT
Cell Rep Med; 2024 Jun; 5(6):101587. PubMed ID: 38781964
[TBL] [Abstract][Full Text] [Related]
13. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
14. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies against EBV gp42 show potent
Wu Q; Zhong L; Wei D; Zhang W; Hong J; Kang Y; Chen K; Huang Y; Zheng Q; Xu M; Zeng MS; Zeng YX; Xia N; Zhao Q; Krummenacher C; Chen Y; Zhang X
Emerg Microbes Infect; 2023 Dec; 12(2):2245920. PubMed ID: 37542379
[TBL] [Abstract][Full Text] [Related]
16. Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection.
Zhao GX; Fang XY; Bu GL; Chen SJ; Sun C; Li T; Xie C; Wang Y; Li SX; Meng N; Feng GK; Zhong Q; Kong XW; Liu Z; Zeng MS
Cell Rep Med; 2024 May; 5(5):101573. PubMed ID: 38776874
[TBL] [Abstract][Full Text] [Related]
17. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
19. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus.
Zhu QY; Shan S; Yu J; Peng SY; Sun C; Zuo Y; Zhong LY; Yan SM; Zhang X; Yang Z; Peng YJ; Shi X; Cao SM; Wang X; Zeng MS; Zhang L
Nat Commun; 2021 Nov; 12(1):6624. PubMed ID: 34785638
[TBL] [Abstract][Full Text] [Related]
20. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion.
Zhang X; Hong J; Zhong L; Wu Q; Zhang S; Zhu Q; Chen H; Wei D; Li R; Zhang W; Zhang X; Wang G; Zhou X; Chen J; Kang Y; Zha Z; Duan X; Huang Y; Sun C; Kong X; Zhou Y; Chen Y; Ye X; Feng Q; Li S; Xiang T; Gao S; Zeng MS; Zheng Q; Chen Y; Zeng YX; Xia N; Xu M
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2202371119. PubMed ID: 35917353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
